Biotec Pharmacon (BIOTEC) NOK1
Biotec Pharmacon ASA is a Norway-based biopharmaceutical company that develops, manufactures and markets immune modulating compounds for the human health sectors and marine enzymes used in molecular biology. The Company focuses on new solutions within wound care, cancer therapies and other immune related disease areas. It has a portfolio of patents covering marine gene products for the molecular biology sector, and products with potentials within the pharmaceutical sector, such as beta-1,3/1,6-glucan formulations. Biotec Pharmacon is the parent company of the group and controls two subsidiaries: ArcticZymes AS, which develops and supplies cold adapted and heat labile enzymes to international research reagents and diagnostic companies, and Biotec BetaGlucans AS, which handles all research and development, and manufacturing of beta-glucans within the group.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.